Global gout therapeutics market is expected to gain a profitable progress over the forecast period owing to the factors such as the development of newer therapies which can be used as the add-on therapies with the already available treatment for gout. These novel therapies are mainly targeted for the population who are not responding well with the currently prescribed gout therapeutics. Geriatric population base is more prone to gout is the high impact rendering driver for the growth of gout therapeutics market. Gout therapeutics market is lagging behind in terms of patented molecules. However, the demand for gout therapeutics is expected to increase due to the increasing incidences of gout in men and women. Other drivers for the growth of gout therapeutics market include increasing prevalence of metabolic disorders such as diabetes, and kidney diseases and rising incidences of disease induced habits such as high alcohol consumption, intake of unsaturated fatty acids, and salt consumption. Introduction of novel molecules and advantages associated with them such as high safety, efficacy, and affordability are anticipated to boost the gout therapeutics market growth during the forecast period. Furthermore, presence of supportive government policies towards healthcare and growing awareness amongst the patients are expected to propel the market growth. Stringent government regulations and patent expiry of the blockbuster gout medications are the restraints in gout therapeutics market.
On the basis of product, gout therapeutics market is segmented into Non-steroidal anti-inflammatory Drugs (NSAIDs), colchicine, corticosteroids, xanthine oxidase inhibitors and probenecid. Whereas, colchicine, and corticosteroids are used as a treatment options for gout andXanthine oxidase inhibitors and Probenecid are used as a preventive therapy. Amongst the different gout therapeutics, NSAIDs are used as the first line of treatment. However, Colchicine and steroids are the alternative treatments for those patients who are unable to tolerate or for whom contraindications exist for NSAIDs. NSAIDs, Colchicine and Corticosteroids are the cost effective treatments for gout. However, currently there is increasing prevalence of gout amongst the geriatric population. Old aged people are generally having more incidences of diabetes, heart diseases and other disorders. This interprets that there is a definite need emerging in the gout therapeutics market for newer and safer treatment options for the patients who are not responding well to the existing gout therapeutics.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market
Geographically, overall gout therapeutics market is segmented into North America, Europe, Latin America, Asia Pacific, and MEA. As of 2014, North America and Europe are the dominating segments because of the important growth factors such as rising prevalence of disease condition and presence of pipeline drugs for the gout treatment. Growing number of R&D initiatives in North America and Europe pertaining to the development of gout therapeutics, higher disposable income, and encouraging healthcare infrastructure are the major factors contributing for its high share. Asia Pacific is expected to be the fastest growing market primarily due to the factors such as rapidly improvising healthcare policies, presence of government initiatives, and rising awareness about the disease condition amongst the population. Furthermore, rising demand for newer and safer gout therapeutics in the emerging markets like India and China, increase the growth opportunities in this region are other drivers for the growth of this market.
Major players contributing to the gout therapeutics market includes Takeda, Novartis, Savient Pharmaceuticals, Regeneron Pharmaceuticals and Teijin Pharma. In the last several years, many pharmaceutical companies have expanded their product portfolios with respect to the gout therapeutics market. Moreover, the companies are focusing upon unmet market requirements and enhancing overall quality that leads to better patient treatment. Increasing R&D and rising strategic acquisitions pertaining to the introduction of new products with better efficacy and safety into the gout therapeutics market. Number of pharmaceutical companies have either acquired or entered into strategic licensing deals with companies possessing potential products for the gout therapeutics market. In 2012, URL Pharma is acquired by Takeda and the acquisitions of pharmaceutical product portfolio of AstraZeneca by BioPhausia have been the major acquisitions in the gout therapeutics market. These strategic acquisitions and licensing deals are expected to help the licensee and acquirer companies to expand their product portfolios, which will in turn make the market more competitive and lucrative as well.
Read detailed report or request for sample of this research report TOC:
http://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market/request-toc
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: www.grandviewresearch.com
On the basis of product, gout therapeutics market is segmented into Non-steroidal anti-inflammatory Drugs (NSAIDs), colchicine, corticosteroids, xanthine oxidase inhibitors and probenecid. Whereas, colchicine, and corticosteroids are used as a treatment options for gout andXanthine oxidase inhibitors and Probenecid are used as a preventive therapy. Amongst the different gout therapeutics, NSAIDs are used as the first line of treatment. However, Colchicine and steroids are the alternative treatments for those patients who are unable to tolerate or for whom contraindications exist for NSAIDs. NSAIDs, Colchicine and Corticosteroids are the cost effective treatments for gout. However, currently there is increasing prevalence of gout amongst the geriatric population. Old aged people are generally having more incidences of diabetes, heart diseases and other disorders. This interprets that there is a definite need emerging in the gout therapeutics market for newer and safer treatment options for the patients who are not responding well to the existing gout therapeutics.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market
Geographically, overall gout therapeutics market is segmented into North America, Europe, Latin America, Asia Pacific, and MEA. As of 2014, North America and Europe are the dominating segments because of the important growth factors such as rising prevalence of disease condition and presence of pipeline drugs for the gout treatment. Growing number of R&D initiatives in North America and Europe pertaining to the development of gout therapeutics, higher disposable income, and encouraging healthcare infrastructure are the major factors contributing for its high share. Asia Pacific is expected to be the fastest growing market primarily due to the factors such as rapidly improvising healthcare policies, presence of government initiatives, and rising awareness about the disease condition amongst the population. Furthermore, rising demand for newer and safer gout therapeutics in the emerging markets like India and China, increase the growth opportunities in this region are other drivers for the growth of this market.
Major players contributing to the gout therapeutics market includes Takeda, Novartis, Savient Pharmaceuticals, Regeneron Pharmaceuticals and Teijin Pharma. In the last several years, many pharmaceutical companies have expanded their product portfolios with respect to the gout therapeutics market. Moreover, the companies are focusing upon unmet market requirements and enhancing overall quality that leads to better patient treatment. Increasing R&D and rising strategic acquisitions pertaining to the introduction of new products with better efficacy and safety into the gout therapeutics market. Number of pharmaceutical companies have either acquired or entered into strategic licensing deals with companies possessing potential products for the gout therapeutics market. In 2012, URL Pharma is acquired by Takeda and the acquisitions of pharmaceutical product portfolio of AstraZeneca by BioPhausia have been the major acquisitions in the gout therapeutics market. These strategic acquisitions and licensing deals are expected to help the licensee and acquirer companies to expand their product portfolios, which will in turn make the market more competitive and lucrative as well.
Read detailed report or request for sample of this research report TOC:
http://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market/request-toc
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: www.grandviewresearch.com
No comments:
Post a Comment